This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Cardiovascular System  • Quality of Life  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial

Matthias Pfisterer, MD; Peter Buser, MD; Hans Rickli, MD; Marc Gutmann, MD; Paul Erne, MD; Peter Rickenbacher, MD; André Vuillomenet, MD; Urs Jeker, MD; Paul Dubach, MD; Hansjürg Beer, MD; Se-Il Yoon, MD; Thomas Suter, MD; Hans H. Osterhues, MD; Michael M. Schieber, MD; Patrick Hilti, MD; Ruth Schindler, RN; Hans-Peter Brunner-La Rocca, MD; for the TIME-CHF Investigators

JAMA. 2009;301(4):383-392.

Context  It is uncertain whether intensified heart failure therapy guided by N-terminal brain natriuretic peptide (BNP) is superior to symptom-guided therapy.

Objective  To compare 18-month outcomes of N-terminal BNP–guided vs symptom-guided heart failure therapy.

Design, Setting, and Patients  Randomized controlled multicenter Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) of 499 patients aged 60 years or older with systolic heart failure (ejection fraction 45%), New York Heart Association (NYHA) class of II or greater, prior hospitalization for heart failure within 1 year, and N-terminal BNP level of 2 or more times the upper limit of normal. The study had an 18-month follow-up and it was conducted at 15 outpatient centers in Switzerland and Germany between January 2003 and June 2008.

Intervention  Uptitration of guideline-based treatments to reduce symptoms to NYHA class of II or less (symptom-guided therapy) and BNP level of 2 times or less the upper limit of normal and symptoms to NYHA class of II or less (BNP-guided therapy).

Main Outcome Measures  Primary outcomes were 18-month survival free of all-cause hospitalizations and quality of life as assessed by structured validated questionnaires.

Results  Heart failure therapy guided by N-terminal BNP and symptom-guided therapy resulted in similar rates of survival free of all-cause hospitalizations (41% vs 40%, respectively; hazard ratio [HR], 0.91 [95% CI, 0.72-1.14]; P = .39). Patients' quality-of-life metrics improved over 18 months of follow-up but these improvements were similar in both the N-terminal BNP–guided and symptom-guided strategies. Compared with the symptom-guided group, survival free of hospitalization for heart failure, a secondary end point, was higher among those in the N-terminal BNP–guided group (72% vs 62%, respectively; HR, 0.68 [95% CI, 0.50-0.92]; P = .01). Heart failure therapy guided by N-terminal BNP improved outcomes in patients aged 60 to 75 years but not in those aged 75 years or older (P < .02 for interaction)

Conclusion  Heart failure therapy guided by N-terminal BNP did not improve overall clinical outcomes or quality of life compared with symptom-guided treatment.

Trial Registration  isrctn.org Identifier: ISRCTN43596477

Author Affiliations: Department of Cardiology, University Hospital Basel, Basel, Switzerland (Drs Pfisterer, Buser, and Brunner-La Rocca, and Ms Schindler); Department of Cardiology, Kantonsspital St Gallen, St Gallen, Switzerland (Dr Rickli); Department of Internal Medicine, University Hospital Liestal, Liestal, Switzerland (Dr Gutmann); Department of Internal Medicine, Kantonsspital Lucerne, Lucerne, Switzerland (Dr Erne); Department of Internal Medicine, University Hospital Bruderholz, Bruderholz, Switzerland (Dr Rickenbacher); Department of Internal Medicine, Kantonsspital Aarau, Aarau, Switzerland (Dr Vuillomenet); Department of Internal Medicine, Kantonales Spital Wolhusen, Sursee, Switzerland (Dr Jeker); Department of Internal Medicine, Kantonsspital Chur, Chur, Switzerland (Dr Dubach); Department of Internal Medicine, Kantonsspital Baden, Baden, Switzerland (Dr Beer); Department of Internal Medicine, Kantonales Spital Sursee, Sursee, Switzerland (Dr Yoon); Department of Cardiology, University Hospital Berne, Bern, Switzerland (Dr Suter); Department of Internal Medicine, Kreiskrankenhaus Lörrach, Lörrach, Germany (Dr Osterhues); Department of Cardiology, Robert Bosch Krankenhaus, Stuttgart, Germany (Dr Schieber); and Department of Internal Medicine, Kantonsspital Solothurn, Solothurn, Switzerland (Dr Hilti).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

BNP-Guided Heart Failure Therapy in Older Patients
Emmanuel Bhaskar
JAMA. 2009;301(20):2091.
EXTRACT | FULL TEXT  

BNP-Guided Heart Failure Therapy in Older Patients
Adrian F. Hernandez and Gregg C. Fonarow
JAMA. 2009;301(20):2091-2092.
EXTRACT | FULL TEXT  

RELATED ARTICLE

BNP-Guided Therapy for Heart Failure
Ileana L. Piña and Christopher O’Connor
JAMA. 2009;301(4):432-434.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure.
Miller et al.
J Am Coll Cardiol 2009;54:1715-1721.
ABSTRACT | FULL TEXT  

Are Multiple Biomarker Testing Strategies Ready for Prime Time in Heart Failure?
Lee and Tu
Circ Heart Fail 2009;2:387-388.
FULL TEXT  

Response to Letters Regarding Article, "Tissue Doppler Imaging in the Estimation of Intracardiac Filling Pressure in Decompensated Patients With Advanced Systolic Heart Failure"
Mullens et al.
Circulation 2009;120:e49-e49.
FULL TEXT  

Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF
Cleland et al.
Eur J Heart Fail 2009;11:802-805.
ABSTRACT | FULL TEXT  

Natriuretic Peptide Measurements in Managing Heart Failure: In Theory and in Practice
Tang
Circ Heart Fail 2009;2:380-381.
FULL TEXT  

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
Blair et al.
Eur Heart J 2009;30:1666-1673.
ABSTRACT | FULL TEXT  

Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): A Randomized Controlled Trial of the Effect of Serial B-Type Natriuretic Peptide Testing on Patient Management
Singer et al.
Circ Heart Fail 2009;2:287-293.
ABSTRACT | FULL TEXT  

BNP-Guided Heart Failure Therapy in Older Patients
Bhaskar
JAMA 2009;301:2091-2091.
FULL TEXT  

BNP-Guided Heart Failure Therapy in Older Patients
Hernandez and Fonarow
JAMA 2009;301:2091-2092.
FULL TEXT  

All you need to read in the other general journals
BMJ 2009;338:b409-b409.
FULL TEXT  

BNP-Guided Therapy for Heart Failure
Pina and O'Connor
JAMA 2009;301:432-434.
FULL TEXT  

BNP-Guided Heart Failure Therapy: Not for Everyone
Journal Watch Cardiology 2009;2009:1-1.
FULL TEXT